PLEGRIDY (peginterferon beta-1a), disease modifying therapy for multiple sclerosis
NEUROLOGY - New medicinal product
Opinions on drugs - Posted on Aug 24 2015
Reason for request
No clinical benefit demonstrated in the treatment of the relapsing-remitting multiple sclerosis (RRMS) compared with existing treatments
- PLEGRIDY has a Marketing Authorisation in the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS).
- It is an alternative to other first-line disease modifying therapies indicated in RRMS.
- Its efficacy versus placebo has been demonstrated. PLEGRIDY, administered subcutaneously once every 2 weeks, has not shown any clinical added value compared with available therapies.
Clinical Added Value
|no clinical added value||
Évaluation des médicaments